Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: p.G12C-mutated pancreatic cancer are unknown. METHODS: p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy. The primary objective of phase 1 was to assess safety and to identify the recommended dose for phase 2. In phase 2, patients received sotorasib at a dose of 960 mg orally once daily. The primary end point for phase 2 was a centrally confirmed objective response (defined as a complete or partial response). Efficacy end points were assessed in the pooled population from both phases and included objective response, duration of response, time to objective response, disease control (defined as an objective response or stable disease), progression-free survival, and overall survival. Safety was also assessed. RESULTS: The pooled population from phases 1 and 2 consisted of 38 patients, all of whom had metastatic disease at enrollment and had previously received chemotherapy. At baseline, patients had received a median of 2 lines (range, 1 to 8) of therapy previously. All 38 patients received sotorasib in the trial. A total of 8 patients had a centrally confirmed objective response (21%; 95% confidence interval [CI], 10 to 37). The median progression-free survival was 4.0 months (95% CI, 2.8 to 5.6), and the median overall survival was 6.9 months (95% CI, 5.0 to 9.1). Treatment-related adverse events of any grade were reported in 16 patients (42%); 6 patients (16%) had grade 3 adverse events. No treatment-related adverse events were fatal or led to treatment discontinuation. CONCLUSIONS: p.G12C-mutated advanced pancreatic cancer who had received previous treatment. (Funded by Amgen and others; CodeBreaK 100 ClinicalTrials.gov number, NCT03600883.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CodeBreaK100 (NCT03600883) clinical trial evaluated the safety and efficacy of sotorasib in advanced KRASG12C-mutant cancers, including 38 patients with metastatic, previously chemotherapy-treated PDAC. In these patients, a 21% objective response rate (ORR), a median progression-free survival (PFS) of 4.0 months, and a median overall survival (OS) of 6.9 months were observed (26).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [26]
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [16]
In the citing paper
“In the first published clinical series of KRASG12C inhibitor monotherapy in advanced PDAC, responses occurred in a minority of patients (~21%) and were generally transient75.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [75]
In the citing paper
“Even with recent advances in this space, currently only inhibitors targeting a specific KRAS mutation (KRAS G12C) have been FDA-approved in NSCLC (2–5).”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [5]
In the citing paper
“Although recently developed KRAS G12C inhibitors, 10 including sotorasib and adagrasib, have shown antitumor activity in patients with previously treated KRAS G12C-mutated cancer, the extent of the clinical benefit remains limited, and better therapies to target KRAS G12C remain a high priority.[11][12][13][14][15][16][17][18]”
From Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation (2023) · cites this paper as [15]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citation
Cited by
Items 201–300 of 579
Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions
Netto, D., Frizziero, M., Foy, V., McNamara, M. G., Backen, A. C., & Hubner, R. A. (2024) · Current Oncology · doi:10.3390/curroncol31090385 · Cited by 8
Seufferlein, T. T. W., Mayerle, J. V., Boeck, S. H., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2338-3533 · Cited by 12
Campbell, B. A., Solinas, D., Blackford, A. L., Molin, M. D., Purchla, J., McPhaul, T. J., Chidambaram, S., Cameron, J. L., Lin, M., Hruban, R. H., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006794 · Cited by 8
The application of pancreatic cancer organoids for novel drug discovery
Melzer, M. K., Resheq, Y. J., Navaee, F., & Kleger, A. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2194627 · Cited by 9
ESMO 2023 pancreatic cancer guidelines signal stepwise progress
Springfeld, C., Bailey, P. J., Büchler, M. W., & Neoptolemos, J. P. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-24-37 · Cited by 8
Swain, S., Narayan, R. K., & Mishra, P. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1461278 · Cited by 7
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma
Sun, J. X., Awad, M. A., Hwang, J., & Villano, A. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15060236 · Cited by 7
Oligometastatic pancreatic cancer: current state of management and emerging therapies
Khomiak, A., Balmaceda, N. B., Ghaffar, S. A., Lieu, C. H., Chiaro, M. D., Messersmith, W. A., & Lentz, R. W. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf154 · Cited by 7
KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Wei, Y., Liu, M., Yen, E.-Y., Yao, J., Xun, Z., Nguyen, P. T.-M., Wang, X., Yang, Z., Yousef, A. M. G., Pan, D. N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2024 · Cited by 7
Safa, A., Vruzhaj, I., Gambirasi, M., & Toffoli, G. (2025) · Cancers · doi:10.3390/cancers17213506 · Cited by 7
Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer
Tiede, K. O. M., Teixeira, M. F., Moura, M., Chiaini, O., Moura, F., Sonbol, M. B., Borad, M. J., Bekaii‐Saab, T., & Usón, P. L. S. (2026) · Scientific Reports · doi:10.1038/s41598-026-40757-3 · Cited by 7
Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma
Lee, J. J., & Yeh, J. J. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.04.001 · Cited by 7
Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations
Maki, R., Iwagami, Y., Kobayashi, S., Sasaki, K., Yamada, D., Tomimaru, Y., Sakai, D., Noda, T., Asaoka, T., Takahashi, H., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17482-8 · Cited by 7
What’s been Hapten-ing over the last 88 years?
Thomson, P., Hammond, S., Meng, X., & Naisbitt, D. J. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03091-1 · Cited by 7
Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
Liu, M., & Wei, A. C.-C. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.01.004 · Cited by 7
Pancreatic cancer: new approaches to drug therapy
Picozzi, V. J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000000877 · Cited by 8
Fuentes, H. E., Kasi, P. M., Ma, L., Hart, L. L., Wong, J., Spigel, D. R., Schnabel, C. A., Reeves, J. A., Halfdanarson, T. R., Treuner, K., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00191 · Cited by 7
Hung, L., Huang, C., Tung, K.-C., Chen, J., Huang, W., Hsu, C., Fang, Y., Wang, C., Liu, P., Yeh, K., et al. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.09.001 · Cited by 7
Müller, M., & Tougeron, D. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-1629 · Cited by 7
Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 7
Eslinger, C. R., Sonbol, M. B., George, B., Babiker, H., Borad, M. J., & Bekaii‐Saab, T. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559325 · Cited by 6
Maloney, S., Clarke, S. J., Sahni, S., Hudson, A. L., Colvin, E. K., Mittal, A., Samra, J. S., & Pavlakis, N. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05149-4 · Cited by 6
New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma
Lee, Y., Im, J.-E., Yang, Y., Lee, H. J., Lee, M. R., Woo, S. M., Park, S., Kong, S., Kim, J. Y., Hwang, H., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00632 · Cited by 7
Global molecular landscape of early MASLD progression in human obesity
Zhao, Q., Nardo, W. D., Wang, R., Zhong, Y., Keles, U., Sakalauskaite, G., Zhao, L. N., Tay, H., Youhanna, S. C., Yan, M., et al. (2026) · eLife · doi:10.1101/2025.01.13.632747 · Cited by 9
Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects
Boubaddi, M., Rossi, J., Marichez, A., Marty, M., Amintas, S., Laurent, C., & Dabernat, S. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17062-w · Cited by 6
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.01 · Cited by 6
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma
Heumann, P., Albert, A., Gülow, K., Tümen, D., Müller, M., & Kandulski, A. (2024) · Cancers · doi:10.3390/cancers16091690 · Cited by 6
Ciulla, C., & Luchini, C. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2348676 · Cited by 6
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Kim, Y., Song, J., Kim, N., & Sim, T. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00881b · Cited by 6
Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy
Jiang, M., Ma, S., Xuan, Y., & Chen, K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117626 · Cited by 6
Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?
Oei, S. L., & Schad, F. (2023) · Cancers · doi:10.3390/cancers15041116 · Cited by 6
Schroeder, B., Mandelson, M. T., & Picozzi, V. J. (2023) · Cancers · doi:10.3390/cancers15235588 · Cited by 6
Ding, Y., Su, H., Shu, Y., & Chen, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30437 · Cited by 6
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-025-03286-w · Cited by 5
Lavacchi, D., Polvani, S., Taddei, A., Scolari, F., Messerini, L., Caliman, E., Moraldi, L., Guidolin, A., Grazi, G. L., Galli, A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1295936 · Cited by 5
Toriyama, K., Masago, K., Shibata, N., Haneda, M., Kuwahara, T., Natsume, S., Kobayashi, S., Fujita, Y., Sasaki, E., Yamao, K., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6432 · Cited by 6
Functional Precision in Pancreatic Cancer: Redefining Biomarkers with Patient-Derived Organoids
Chew, C. A. Z., Wun, C. M., Lee, Y. F., Chee, C. E., Ho, K. Y., & Bonney, G. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189083 · Cited by 6
Li, R., Hu, Y., Liu, Y., & Tan, X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1548027 · Cited by 8
Silva, H. M., & Rosa, R. C. A. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00323-w · Cited by 5
Molecular Pathology of Pancreatic Ductal Adenocarcinoma
Shalaby, A. S., Sadri, N., & Xue, Y. (2025) · Cancers · doi:10.3390/cancers17213549 · Cited by 8
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Fojo, T., LaRose, M., & Bates, S. E. (2024) · The Oncologist · doi:10.1093/oncolo/oyae042 · Cited by 5
Advances in Systemic Therapy in Pancreatic Cancer
Yu, K. H. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.002 · Cited by 5
Huang, S., Yang, J., Xie, T., Jiang, Y., Hong, Y., Liu, X., He, X., Buratto, D., Zhang, D., Zhou, R., et al. (2024) · Advanced Science · doi:10.1002/advs.202401845 · Cited by 6
Personalized treatment using predictive biomarkers in solid organ malignancies: A review
Tang, H., Li, Y. X., Lian, J. J., Ng, H.-Y., & Wang, S. S. Y. (2024) · Tumori Journal · doi:10.1177/03008916241261484 · Cited by 5
Ahmed, M., Larson, B. K., Osipov, A., Azad, N. A., & Hendifar, A. E. (2024) · Oncotarget · doi:10.18632/oncotarget.28659 · Cited by 5
Kishiwada, M., Mizuno, S., Hayasaki, A., Kaluba, B., Fujii, T., Noguchi, D., Ito, T., Iizawa, Y., Tanemura, A., Murata, Y., et al. (2025) · Cancers · doi:10.3390/cancers17061048 · Cited by 5
Rekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 7
Companion Tests and Personalized Cancer Therapy: Reaching a Glass Ceiling
Ferrari, V., Mograbi, B., Gal, J., & Milano, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189991 · Cited by 5
Molecular Characterization and Clinical Relevance of MGMT‐Silenced Pancreatic Cancer
Nichetti, F., Silvestri, M., Agnelli, L., Franza, A., Pircher, C. C., Rota, S., Ambrosini, P., Fotia, G., Hüllein, J., Randon, G., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70393 · Cited by 5
Jobu, Y., Nishigawa, M., Furihata, K., Furihata, M., Uchida, K., & Taniuchi, K. (2025) · Human Cell · doi:10.1007/s13577-024-01165-9 · Cited by 5
Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
Cherri, S., Melocchi, L., Gandolfi, L., Rossi, G., & Zaniboni, A. (2023) · Life · doi:10.3390/life13020395 · Cited by 5
García-Román, S., Garzón‐Ibáñez, M., Bertrán-Alamillo, J., Jordana‐Ariza, N., Giménez-Capitán, A. A., García‐Peláez, B., Vives-Usano, M., Codony‐Servat, J., d'Hondt, E., Rosell, R., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101878 · Cited by 4
Faber, E. B., Baca, Y., Xiu, J., Walker, P., Manji, G. A., Gholami, S., Saeed, A., Prakash, A., Botta, G. P., Sohal, D. P. S., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100042 · Cited by 5
Pillai, A. B., Yousef, M., Yousef, A. M. G., Alfaro-Munoz, K. D., Smaglo, B. G., Willis, J. A., Wolff, R. A., Pant, S., Hurd, M. W., Maitra, A., et al. (2024) · Cancers · doi:10.3390/cancers16193421 · Cited by 4
Long Non-Coding RNAs and RNA-Binding Proteins in Pancreatic Cancer Development and Progression
Preckwinkel, P., Mir, K. U. I., Otto, F. W., Elrewany, H., Sinz, A., Hüttelmaier, S., Bley, N., & Gutschner, T. (2025) · Cancers · doi:10.3390/cancers17101601 · Cited by 4
Napoli, N., Ripolli, A., Kauffmann, E. F., Ginesini, M., Casadei, R., Coppola, R., Egorov, V., Nagakawa, Y., Rangelova, E. B., Vicente, E., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18212-w · Cited by 4
Oscanoa, J., Ross‐Adams, H., Ullah, A. Z. M. D., Kolvekar, T. S., Sivapalan, L., Gadaleta, E., Thorn, G. J., Abdollahyan, M., Imrali, A., Saad, A. B., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102550 · Cited by 6
Roles of nucleotide metabolism in pancreatic cancer
Liu, Q., Liu, J., Wang, S., Bao, N., Zhao, X., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1637768 · Cited by 6
Precision medicine strategy in pancreatic ductal adenocarcinoma
Tarabay, A., Swales, L. A., Smolenschi, C., Akoury, E., Valéry, M., Fuerea, A. C., Pudlarz, T., Boige, V., Rouleau, É., Gelli, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105899 · Cited by 4
Self-citationMetastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment
Debiais, M., Tarabay, A., Blanchet-Deverly, S., Camilleri, G. M., Megherbi, A., Diebakate, L., Collin, M., Hollebecque, A., Smolenschi, C., Valéry, M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116160 · Cited by 4
Self-citationCurrent Systemic Treatment Options for Advanced Pancreatic Cancer—An Overview Article
Domagała-Haduch, M., Długaszek, A., Gorzelak-Magiera, A., & Gisterek, I. (2026) · Biomedicines · doi:10.3390/biomedicines14010188 · Cited by 4
Targeting the gut-pancreatic axis: microbial modulation of immunotherapy in pancreatic cancer
Yuan, Y., Zhang, W., & Wang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1682390 · Cited by 4
Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas
Gutmans, J., Friedlaender, A., & Mechahougui, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031597 · Cited by 4
Heckelmann, B., Duhn, J., & Braun, R. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.075028 · Cited by 4
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond
Misirian, A., Pai, J., & Hanna, D. L. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261432058 · Cited by 4
Kerper, A. L., Einarsson, H., Waugh, L., Delgado, A., Smith, C., Jenkins, S. M., Passow, M. R., Majumder, S., & Graham, R. P. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04544-9 · Cited by 4
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
The Landmark Series: The Future of Pancreatic Cancer Clinical Trials
Seo, Y. D., Katz, M. H. G., & Snyder, R. A. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16840-2 · Cited by 4
Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC
Hong, Z., Huang, X., Xia, L., Liang, T., & Bai, X. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03323-9 · Cited by 4
Dbouk, M. H., Davis, B. G., Peller, M. T., Sloan, E., Hollander, T. G., Genere, J. P. R., Bazarbashi, A. N., Ismail, M. T., Lang, G. D., Kushnir, V. M., et al. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2025.03.1208 · Cited by 4
Sotorasib-impaired degradation of NEU1 contributes to cardiac injury by inhibiting AKT signaling
Cheng, M., Wu, W., Li, X., Tao, X., Jiang, F., Li, J., Shen, N., Wang, F., Luo, P., He, Q., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02431-x · Cited by 4
Furukawa, T., Fukada, I., Hayashi, N., Okamoto, T., Sato, Y., Maegawa, Y., Hirai, T., Mie, T., Takeda, T., Sasaki, T., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.06.013 · Cited by 4
yousif, B. J., Alwahab, D. H. A., Mohammed, H., Yasin, Y. S., & Jumaa, A. H. (2025) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2025.26.8.3053 · Cited by 4
Raji, S., Zaribafzadeh, H., Jones, T., Kanu, E. N., Tong, K., Fletcher, A. A., Howell, T. C., McCall, S. J., Marks, J., Rogers, B., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00115 · Cited by 4
Caughey, B. A., Umemoto, K., Green, M. F., Ikeda, M., Lowe, M. E., Ueno, M., Niedzwiecki, D., Taniguchi, H., Walden, D. J., Komatsu, Y., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-114 · Cited by 4
Self-citationGuan, X., Li, Y., Guan, X., Fan, L., & Ying, J. (2024) · PeerJ · doi:10.7717/peerj.16805 · Cited by 4
Lloyd, E. G., Henríquez, J. A., & Biffi, G. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050624 · Cited by 4
Dreikhausen, L., Klupsch, A., Wiest, I., Xiao, Q., Schulte, N., Betge, J., Boch, T., Brochhausen, C., Gaiser, T., Hofheinz, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12261-2 · Cited by 4
Agnostic drug development revisited
Hernando‐Calvo, A., Rossi, A., Vieito, M., Voest, E. E., & Garralda, E. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102747 · Cited by 4
Macarulla, T. M., Martín, A. J. M., de Castro, E. M., Trujillo, O. A. C., Cano, M. T., Castet, F., Tocino, R. V., Arias, A. F., Ghanem, I., Díaz, I. A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100116 · Cited by 5
Achieving the promise and avoiding the peril of chemical probes using genetics
Jones, N. H., & Kapoor, T. M. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102628 · Cited by 4
KRASG12D inhibition in pancreatic cancer: Fas expression facilitates immune clearance
Yeh, C., Park, W., & Yaeger, R. D. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.08.020 · Cited by 4
Self-citationGong, M., Zhang, B., Wang, X., Zhu, Z., Li, W., Han, L., Wu, Z., Ma, Q., Wang, Z., & Qian, W. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000154 · Cited by 4
Tamura, T., Ashida, R., Wan, K., Shimokawa, T., & Kitano, M. (2023) · Pancreatology · doi:10.1016/j.pan.2023.11.012 · Cited by 4
Chao, T., Wang, Z., Bowne, W. B., Yudkoff, C. J., Torjani, A., Swaminathan, V., Kavanagh, T. R., Roadarmel, A., Sholevar, C. J., Cannaday, S., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0005-oa · Cited by 4
Co-fluctuations of genes in single cells predict transcriptome-wide outcomes to perturbationsPreprint
Kuznets-Speck, B., Kumari, N., Senthilkumar, I., Jung, J., Rios, H. M. L., Schwartz, L., Sun, H., Anisetti, V. R., Wang, C., Wang, Q., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.27.661814 · Cited by 4
So, E., Hayashi, H., Shimozaki, K., Horie, S., Kishimoto, S., Chida, A., Saito, Y., Tsugaru, K., Hirata, K., Tanishima, S., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02713-5 · Cited by 3
Kasper, S., & Sebastian, M. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0002 · Cited by 4
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Roy, J., Mouawad, R., Kyani, A., Hanafi, M., Xu, Y., Wen, B., Sun, D., & Neamati, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03159 · Cited by 3
Bae, A.-N., Mortaja, M., Yeung, Y., Huang, J., Park, J. H., & Demehri, S. (2025) · Cancers · doi:10.3390/cancers17132087 · Cited by 3
A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy
Goloudina, A. R., Chevalier, F. L., Authié, P., Ciret, S., Nemirov, K., Fert, I., Moncoq, F., Vesin, B., Noirat, A., Blanc, C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05134-6 · Cited by 3
Yuan, Z., Ma, S., Liang, Y., Xu, M., Liu, D., Wang, W., Han, B., Chen, G., & Wang, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-08431-2 · Cited by 5
Leng, Q., Zhou, J., Wang, X., Zhang, P., Xu, H., & Cao, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1562481 · Cited by 3
Prediabetes Remission and the Subsequent Risk of Pancreatic Cancer: A Nationwide Cohort Study
Park, J., Hong, J. Y., Han, K., Shen, J. J., Kwon, M., Park, Y. S., Park, J. O., & Lim, H. Y. (2025) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2025.107979 · Cited by 3
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer
Safyan, R. A., & Chiorean, E. G. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102268 · Cited by 4
Koopman, M., García‐Carbonero, R., Pinto, C. M. D. S., Mitroshkin, A., Bodoky, G., Mineur, L., Bourgeois, V., Mare, M., Ruiz‐Casado, A., Montés, A. F., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100214 · Cited by 3
Lee, W., Woo, H.-M., Cho, J. H., & Kim, M. S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1718911 · Cited by 3
Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition
Zhang, Y., Kohno, S., Gao, K., Hasan, M., Baba, T., Zhang, Z., Sankoda, N., Yu, H., Pan, J., Gotoh, N., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01634-0 · Cited by 3
Hu, Z., Sha, Z., Martí, J., Guo, S., & Tao, S. (2026) · JACS Au · doi:10.1021/jacsau.5c01097 · Cited by 3
Metadata
- Authors
- Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., Vincent, M., Sunakawa, Y., Dahan, L., Bajor, D., Rha, S.-Y., Lemech, C., Juric, D., Rehn, M., Ngarmchamnanrith, G., Jafarinasabian, P., Tran, Q., & Hong, D. S.
- Affiliations
- Kansai Medical University (JP)
- From Duke University Medical Center, Durham, NC (J.H.S.); Kansai Medical University, Shinmachi, Hirakata (H.S.), and St. Marianna University School of Medicine, Kawasaki (Y.S.) — both in Japan; University of Florida, Gainesville (T.J.G.); Memorial Sloan Kettering Cancer Center, New York (R.Y.); Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif (A.H.), and Marseille University Hospital, Marseille (L.D.) — both in France; Huntsman Cancer Institute, University of Utah, Salt Lake City (I.G.-L.); West German Cancer Center, University Hospital Essen, Essen (M.S.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (T.F.B.); Fred Hutchinson Cancer Center, University of Washington, Seattle (A.L.C.); Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); London Regional Cancer Program, London, ON, Canada (M.V.); University Hospitals Cleveland Medical Center, Cleveland (D.B.); Yonsei Cancer Center, Seoul, South Korea (S.-Y.R.); Scientia Clinical Research and Prince of Wa...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-05
- Volume
- 388
- Issue
- 1
- Pages
- 33-43
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10506456
- OpenAlex
- W4312094134
- Semantic Scholar
- 488922b069e36918a499827187276c02b891cb58
- Cited by
- 527
- References
- 34
- Citations by year
- 2026: 138 · 2025: 169 · 2024: 142 · 2023: 78
- FWCI
- 40.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Amgen Inc.
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- sotorasib, KRAS G12C mutation, advanced pancreatic cancer, KRAS inhibitors, metastatic pancreatic cancer, previously treated patients, objective response, progression-free survival, overall survival, treatment safety, adverse events
- MeSH terms
- Immune Checkpoint Inhibitors, Administration, Oral, Humans, Lung Neoplasms, Mutation, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.